Medicare In The Business Of Setting ‘Fair’ Drug Prices: How Will Value Factor In?
Executive Summary
New law directs HHS to consider comparative effectiveness information as it approaches price negotiations with manufacturers. But it’s not clear what that means and stakeholders will watch for greater clarity from implementing regulations. ICER’s Steve Pearson weighs in on what they might say.
You may also be interested in...
Republican Leaders In Congress Want To Undercut Drug Pricing Law: What’s The Opportunity?
As Republicans expand their power in Congress, experts weigh in on prospects for significant changes to the Medicare price negotiation law and what the GOP might do to hamper implementation of the program.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.